Best Immunotherapy Companies in London, United Kingdom
The 43 best Immunotherapy companies in London, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Quell.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in London
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Quell Developer of engineered regulatory T cell therapies for immune diseases | $344M | 43 mo ago | 18 | Giovanna Lombardi Co-Founder | Series B | — | — |
| 2 | Achilles Therapeutics Developer of T-cell therapies for cancer | $242M | 49 mo ago | 118 | Charles Swanton Co-Founder | Public | 56 patents Neoantigen discovery and peptide synthesis for personalized cancer immunotherapy | — |
| 3 | Pheon Therapeutics Developer of antibody drug conjugates for treating solid tumor cancers | $188M | 27 mo ago | 8 | Bertrand Damour CEO | Series B | 37 patents Antibody‑drug conjugates targeting CDCP1 and novel cytotoxic small‑molecule therapeutics. | — |
| 4 | Autolus Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases | $181M | 30 mo ago | 51 | Martin Pule Founder | Public | 648 patents CAR‑T immunotherapies targeting CD19 and TRBC antigens with viral vector platforms | 1 award |
| 5 | Mereo BioPharma Developer of therapeutics for cancer and rare diseases | $141M | 74 mo ago | 56 56 → 45 (-20%) | Charles Sermon Co-Founder | Public | 273 patents Anti‑sclerostin antibodies for osteogenesis imperfecta and neutrophil elastase inhibitors for A1AT‑related lung disease | — |
| 6 | Myricx Bio Developer of antibody drug conjugates for the treatment of cancer | $121M | 25 mo ago | 6 | Robin Carr CEO | Series A | — | — |
| 7 | Vicebio Developer of vaccines to treat viral infectious diseases 35Growth top 15%Funding top 26%News top 26%Moat top 47% All 9 signals ▾Growthtop 15% Fundingtop 26% Newstop 26% Moattop 47% Talentbottom 49% Globalbottom 37% Patentsbottom 35% Marketbottom 25% Innovationbottom 22% Growth: Fresh capital in last 24 mo Funding: Raised $100M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $100M | 23 mo ago | 4 | Emmanuel Hanon CEO | Acquired | 2 patents Recombinant chimeric fusion protein vaccines targeting hMPV and RSV antigens. | — |
| 8 | Cytospire Therapeutics Provider of immune cell engagers for treating cancer 53Funding top 24%Global top 45%Talent bottom 49% All 3 signals ▾Fundingtop 24% Globaltop 45% Talentbottom 49% Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 4 countries beyond United Kingdom rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 3 mo ago | — | Natalie Mount CEO | Series A | — | — |
| 9 | Prokarium Developer of bacterial immunotherapy treatments for various types of cancer | $62M | 43 mo ago | 20 20 → 17 (-15%) | Ibraheem Mahmood CEO | Series C | 77 patents Engineered cytokine variants and bacterial vectors for cancer immunotherapy delivery | — |
| 10 | Ixaka Developer of cell-based therapeutic solutions for the treatment of multiple therapeutic conditions | $54M | 67 mo ago | 9 | Vicente Gonzalez Co-Founder | Deadpooled | — | — |
| 11 | Epsilogen Developer of immunoglobulinE antibodies for the treatment of cancer | $54M | 23 mo ago | 4 | Tim Wilson CEO at Epsilogen Ltd | Series B | 19 patents Engineered heteromultimeric IgE/IgG antibodies targeting low‑HER2 tumors | — |
| 12 | Adaptate Biotherapeutics Developer of T-cell based immunotherapy for treating cancer | $34M | 64 mo ago | 21 | — | Acquired | 4 patents Targeted antibody therapeutics against TCR delta variable 1 antigens | — |
| 13 | PrEP Biopharm Developing RNA based immunomodulators for the prevention of respiratory infections | $32M | 129 mo ago | 118 | — | Series A | — | — |
| 14 | Tiziana Life Sciences Developer of small-molecule drugs for cancer and autoimmune diseases | $22M | 81 mo ago | 11 | — | Public | 79 patents Patents concentrated in chemistry & materials | — |
| 15 | Treos Bio Developer of cancer vaccines and companion diagnostics | $22M | 64 mo ago | 12 12 → 16 (+33%) | — | Series B | 65 patents Personalized peptide-based cancer vaccines and immunogenic peptide discovery platforms. | — |
| 16 | Leucid Bio Developer of therapeutics for the treatment of cancers | $22M | 62 mo ago | 10 10 → 23 (+130%) | John Maher Co-Founder | Series A | — | — |
| 17 | Immune Targeting Systems Vaccines against mutating viruses | $20M | 197 mo ago | 46 | — | Acqui-Hired | 36 patents Fluorocarbon‑linked peptide vaccine delivery platforms for infectious and cancer immunotherapy | — |
| 18 | Valink Therapeutics Developer of bispecific antibody-drug conjugate therapeutics for oncology and other diseases | $20M | 10 mo ago | — | Irsyad Khairil Co-Founder & CTO | Seed | — | — |
| 19 | Capella Bioscience Monoclonal antibodies (mAbs) in oncology and autoimmune disease. | $18M | 103 mo ago | 3 | — | Series A | 24 patents Therapeutic antibodies targeting immune receptors (LIGHT, BDCA‑2, PD‑L1) for immunomodulation | — |
| 20 | Macrophage Pharma Developer of small molecule drugs targeting tumor-associated macrophages | $11M | 108 mo ago | 7 | — | Series A | 54 patents Immuno‑oncology cytokine induction (IL‑12) and p38 MAPK inhibitor small‑molecule therapeutics | — |
| 21 | NK:IO Developer of small molecule therapies for hematological and solid tumors | $7M | 20 mo ago | 1 | Matthew Fuchter Co-Founder | Seed | — | — |
| 22 | Evariste AI-based drug discovery platform to target synthetic lethal pathways in oncology | $4M | 36 mo ago | 9 | Anna Hercot CEO | Seed | — | — |
| 23 | VacV Developer of immuno-therapeutics for cancer treatment | $3M | 45 mo ago | 6 | Peng Liu Co-Founder | Seed | — | — |
| 24 | IQur Therapeutics Vaccines for influenza, malaria, human cytomegalovirus, dengue fever and hepatitis C | $2M | 127 mo ago | 3 | William Rosenberg CEO | Series A | — | — |
| 25 | Siftr Bio Developer of antibofy drug conjugates for cancer treatment | $1M | 20 mo ago | — | Ed Tate Co-Founder | Seed | — | — |
| 26 | Bastion Therapeutics Developer of cell therapy for inflammatory disorders and autoimmune diseases | $1M | 30 mo ago | — | Nia Emami Co-Founder & CSO | Seed | — | — |
Top 12 Immunotherapy companies in London
#1
Series A · London, England · founded 2023$83Mraised▾
Provider of immune cell engagers for treating cancer. It offers a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells to discriminate between target diseased vs healthy cell for the treatment of solid tumors and other cancer.
- May 2026Series A$83M
- Seed—
#2
Seed · London, England · founded 2020$19.6Mraised▾
Developer of bispecific antibody-drug conjugate therapeutics for oncology and other diseases. The company focuses on creating more effective drugs that differentiate between diseased and healthy cells. It utilizes a discovery engine built on synthetic protein biology, high-throughput functional screening, and artificial intelligence. The company is advancing oncology-focused programs.
- Oct 2025Seed$11.8M
- Nov 2023Seed$7.8M
#3
Acquired · London, England · founded 2019 · 4 employees$100Mraised▾
Developer of vaccines to treat viral infectious diseases. The company has Molecular Clamp technology for high yield production of viral fusion proteins in native trimeric “prefusion” form. The lead candidate of the company includes VXB-211 which targets respiratory syncytial virus (RSV). The company has developed a pipeline for Metapneumovirus, influenza, and SARS-CoV-2.
- Sep 2024Series B$100M
#4
Series B · London, England · founded 2016 · 4 employees$53.8Mraised▾
Developer of immunoglobulin antibodies for the treatment of cancer. It offers antibodies that help in the treatment of solid tumors. The lead product candidate, MOv18 IgE is for folate receptor alpha positive cancer patients. Other products include EPS 201 for breast cancer and gastric problems.
- Sep 2024Series B$16.4M
- Mar 2022Series B$41.1M
- Oct 2020Grant (prize money)—
- Jul 2020Grant (prize money)$627.7K
#5
Series B · London, England · founded 2022 · 8 employees$188Mraised▾
Developer of antibody drug conjugates for treating solid tumor cancers. These therapeutic agents utilize monoclonal antibodies to target specific proteins on cancer cells. The technology employs proprietary payloads and linker combinations to deliver cytotoxic agents directly to tumor sites. This approach aims to balance safety and efficacy by minimizing exposure to healthy tissue while addressing unmet medical needs in oncology.
- May 2024Series B$120M
- Sep 2022Series A$68M
#6
Series A · London, England · founded 2019 · 6 employees$120.6Mraised▾
Developer of antibody drug conjugates for the treatment of cancer. The company focuses on the development of a pipeline of proprietary differentiated antibody drug conjugates based on novel N-myristoyltransferase inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology.
- Jul 2024Series A$114M
- Oct 2019Seed$6.6M
#7
Public · London, England · founded 2015 · 51 employees$181.4Mraised▾
Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases. It leverages advanced immune cell engineering, chimeric antigen receptor (CAR) technology, and proprietary T cell programming platforms to create precise, controlled, and highly active therapeutic products designed to improve patient outcomes. Its technology platform combines innovative cell programming capabilities with proprietary viral vector systems and semi-automated manufacturing processes to engineer patient-derived T cells capable of recognizing and eliminating disease-causing cells.
- Feb 2024Post IPO$200M
- Nov 2021Post IPO—
- Sep 2017Series C$80M
- Mar 2016Series B$56M
#8
Series B · London, England · founded 2019 · 18 employees$344.2Mraised▾
Developer of engineered regulatory T cell therapies for immune diseases. This clinical-stage organization focuses on modifying a patient's own regulatory T cells to restore immune balance. These therapies aim to address conditions involving autoimmunity, chronic inflammation, and organ transplant rejection by dampening immune responses and preventing tissue damage. The approach utilizes cellular engineering to regulate immune activity and manage severe inflammatory disorders.
- Jan 2023Series B$24.1M
- Mar 2022Series B$57.9M
- Nov 2021Series B$156M
- Dec 2020Series A$34.9M
#9
Seed · London, England · founded 2020 · 1 employees$6.5Mraised▾
Developer of small molecule therapies for hematological and solid tumors. The company is pioneering discoveries in small molecule and peptide ligand activation of blood stem cell progenitors and NK cells for the treatment of cancer.
- Dec 2024Seed$127.3K
- May 2024Seed$973.3K
- Jul 2023Seed$1.5M
- Jul 2023Grant (prize money)$2.1M
#10
Public · London, England · founded 2016 · 118 employees$242Mraised▾
Developer of T-cell therapies for cancer. Its therapeutics will target tumor neo-antigens, unique flags to the immune system present on the surface of every cancer cell. They develop therapeutics for lung cancer, recurrent metastatic melanoma, and head and neck squamous cell carcinomas.
- Jul 2022Grant (prize money)$4.1M
- Jun 2021Grant (prize money)$1M
- Nov 2020Series C$97.5M
- Jul 2019Series B$121M
#11
Series C · London, England · founded 2012 · 20 employees$61.6Mraised▾
Developer of bacterial immunotherapy treatments for various types of cancer. The company leverages synthetic biology to reprogram bacteria specifically using its proprietary ZH9 strain to function as a therapeutic delivery platform for oncology and other medical applications.
- Jan 2023Series C$30M
- Oct 2020Series B$21.3M
- Oct 2019Grant (prize money)$5.7M
- May 2019Series A$178.8K
#12
Seed · London, England · founded 2024$1.3Mraised▾
Developer of antibofy drug conjugates for cancer treatment. It uses SIFTR platform to drive high throughput ADC linker development with specific low-side-effect tumour-killing drugs that are only activated when they reach solid tumours.
- Dec 2024Seed$1.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology in London is moving
A read on the academic research around Immunology in London — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 466 papers.
- King\'s College London135
- University College London124
- Imperial College London113
- Queen Mary University of London58
- London Cancer26
- Immunotherapy5→31
- Immune system5→31
- Tumor microenvironment2→13
- Autoantibody1→8
- Chimeric antigen receptor4→10
- Immune system5→64
- Immunotherapy6→62
- Cancer1→16
- Chimeric antigen receptor2→13
- Antibody2→11
- Immunotherapy3→31
- Immune system1→20
- Internal medicine1→12
- Cancer1→10
- Antibody1→5
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.